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Abstract 
The incident hemodialysis (HD) population is aging, and the elderly 
group is the one with the most rapid increase. In this context it is im-
portant to define the factors associated with outcomes in the elderly 
patients. The high prevalence of comorbidities, particularly diabetes 
mellitus, peripheral vascular disease and congestive heart failure, 
usually make vascular access (VA) creation more difficult. Further-
more, many of these patients may have an insufficient vasculature 
for fistula maturation. Finally, many fistulas may never be used due 
to the competing risk of death before dialysis initiation. In these cas-
es, an arteriovenous graft and in some cases a central venous cath-
eter become a valid alternative form of VA. Nephrologists need to 
know what is the most appropriate VA option in these patients. The 
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aim of this position statement is to critically review the current evi-
dence on VA in the elderly HD patients. To this purpose the relevant 
clinical studies and recent guidelines on VA are reviewed and com-
mented. Experts of the Vascular Access Working Group of the Italian 
Society of Nephrology prepared this position statement in order to 
discuss the main advantages and potential drawbacks of the differ-
ent VA modalities in the elderly patients.  
 Key words: vascular access, elderly, arteriovenous fistula, arterio-
venous graft, central venous catheter. 
 
Introduction 
Peoples aged over 65 years are increasing worldwide, and it is pre-
dicted that over the next few decades the number of peoples over 65 
years will increase by a factor of three (1). It is estimated that almost 
half of 65-74 year-old peoples have a five or greater chronic health 
conditions, and this may reach 70% once individuals are aged over 
85 years (1). As nephrologists, we are facing increasing numbers of 
elderly patients affected by chronic kidney disease (CKD) and a high 
prevalence of comorbidities such as diabetes mellitus, peripheral 
vascular disease, hypertension and congestive heart failure. Be-
tween 1982 and 2000, the greatest growth in incident hemodialysis 
(HD) patients older than 65 years has been reported (2). The 2012 
Annual Report of the European Renal Association - European Dialy-
sis and Transplant Association (ERA-EDTA) Registry shows that pa-
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tients aged 65-74 years represent 22% of the total prevalent renal 
replacement therapy population, and those aged > 75 years repre-
sent 20% (3). The clinical practical guidelines for the evaluation and 
management of CKD recently published by the Kidney Disease Initi-
ative Global Outcomes (KDIGO) provide only minimal recommenda-
tions targeted for the elderly (4); in addition, renal replacement ther-
apy in the elderly patients raises several critical issues such as life 
expectancy, quality of life, and other moral, ethical, financial, social, 
and legal issues (5). Arteriovenous fistulas (AVFs) are recommend-
ed by many national clinical guidelines as the vascular access (VA) 
of choice in HD patients; however, concerns exist regarding the is-
sue of whether general guidelines could also apply to elderly popula-
tion (6), and suggestions are made how to modify the recommenda-
tions for VA choice in these patients (7). In fact, the VA planning in 
the elderly is different from that in younger patients, and the Fistula 
First Initiative may not be the preferred approach for older patients 
because of their reduced life expectancy and conflicting results after 
surgery (8). Although AVF may be superior to arteriovenous graft 
(AVG) and central venous catheter (CVC) in all age groups, includ-
ing the elderly, many of these patients have a heavy burden of 
comorbidities and insufficient vasculature for fistula maturation, re-
sulting in a reduced rate of AVF patency (9). Patients over 65 years 
have a fistula failure rate two times higher than the younger popula-
tion (10); furthermore, many fistulas will never be used due to the 
competing risk of death before dialysis initiation in this group (11). 
Unsuccessful fistula placement results in high incidence of CVC use 
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at start of HD treatment, with significant risks and complications from 
catheter such as bacteremia and thrombosis (12). However, blood-
stream infections in older patients may be significantly less than in 
younger patients (13). Data about the AVG in the elderly are conflict-
ing. Some studies advocate the use of AVF rather than AVG and 
provide evidence that in the elderlies autogenous VA may have a pa-
tency rate similar to that of younger patients (14). Differently, other 
data support the competing strategy of AVG first in octogenarians 
and show a higher chance of dying before the start of dialysis with 
an AVF over an AVG (15). Patient survival is strongly influenced by 
important factors, such as nutritional status, predialysis nephrology 
care, cardiovascular disease, and most importantly the VA. Nephrol-
ogists should strive for the most appropriate VA if an hope of prolon-
gation of an enjoyable life span exists. The aim of this position 
statement is to critically review the current evidence on HD VA in the 
elderly patients. Experts of the Vascular Access Working Group of 
the Italian Society of Nephrology prepared this position statement in 
order to discuss the main advantages and the potential drawbacks of 
the different VA modalities in the elderly patients. 
Timely VA placement in the elderly 
A predialysis formalized pathway and timely placement of VA are 
considered the good clinical practice in the VA care. Timely prepara-
tion and education for dialysis are crucial, as these are associated 
with a number of benefits, including elective dialysis start with ac-
cess in place, reduction in hospitalizations, higher prevalence of pa-
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tients choosing a home-based dialysis modality, and in those starting 
with HD a reduced prevalence of CVC (16). Older patients loose re-
nal function at slower rates than youngers, have lower rate of events 
of progression to end-stage renal disease (ESRD), and have shorter 
survival (5). The elderly patients may be more likely to die before 
benefiting from an AVF and to experience primary fistula failure with 
a high incidence of CVC use at the HD initiation, which is associated 
with increased morbidity and mortality (17,18). A study population 
has shown that placing an AVF > 9 months before HD start did not 
improve the success rate but was associated with an increased 
number of interventional procedures: from 0.64 procedures/patient 
for AVFs created 6-9 months predialysis to 0.72 procedures/patient 
for AVFs created > 12 months predialysis. In summary, placing an 
AVF > 6-9 months predialysis in the elderly is not associated with a 
better success rate (19). However, the VA teams tend to construct 
AVFs earlier rather than later before HD initiation, although it must 
be recognized that the time between the moment the patient was re-
ferred to a nephrologist and the start of dialysis was 3.5 weeks for 
individuals >75 years vs. 20.5 weeks for those < 75 years (17). This 
would be even better, because some authors suggest that the elder-
ly patients with CKD should be referred later to reduce the risk of 
creating an AVF that is never used (20). In this regard the AVG be-
comes a valid alternative form of VA, if no suitable anatomy for AVF 
creation and slow renal progression are present (21); in these cases, 
the use of early stick graft might be suitable, because of the high risk 
of non-maturing autologous AVF in these patients (22), even though 
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mortality benefit of AVG over CVC may not apply in older (>89 
years) age groups (9). Life expectancy as well as quality of life are 
important aspects for most patients considering dialysis, and recent 
data suggest that, if dialysis is adequately prepared for in advance, it 
is safe to delay its initiation until the development of signs and symp-
toms of uremia (23). In a context of an intent-to-defer strategy for di-
alysis initiation a tunneled CVC could be the best choice, because 
no maturation time is required. Some authors have supported gen-
eralized use of CVC in older patients (24) and, due to the lower risk 
of catheter-related bloodstream infections in elderly patients, tun-
neled CVC may represent a suitable dialysis access option in the 
setting of non-maturing AVF or poorly functioning synthetic grafts 
(13). However, strict protocols for nursing care and proper catheter 
management should be implemented in every center (25). 
 
VA in elderly patients: recent findings 
There is currently no general consensus as to the best dialysis VA 
for elderly patients with ESRD, and debate continues. The elderlies 
need specific health care requirement, as they are at increased risk 
of comorbidities that may result in frailty, reduced physical and cog-
nitive function; furthermore, they often face complex psychosocial, 
financial, and transportation issues (26). The creation and use of a 
VA in elderly patients require the complex integration of patient, bio-
logical and surgical factors because the VA type might be a key fac-
tor influencing their survival (9,2,22,27). The advantages and disad-
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vantages of each form of access may vary depending on the timing 
of the access placement relative to the dialysis initiation (12) The 
summary of the recommendations and suggestions from recently 
published studies on VA in the elderlies are reported in Table 1. 
Many studies clearly demonstrate a high rate of technical feasibility 
of fistula construction in the elderlies (28,29,9,30) and age alone 
should not disqualify patients older than 80 years from access sur-
gery (14,31). Nevertheless, it has been shown that in patients 67 
year-old or older, only 50.7% of those with AVF placement initiated 
dialysis using the AVF, and 43.4% started with a CVC; by contrast, 
among patients that received a graft as first access only 25,4% 
started dialysis with a CVC; in other words, the patients who receive 
a graft are less likely to require a catheter at initiation compared with 
those who receive a fistula (15). In a retrospective cohort study on 
the early failure of dialysis access in the elderly, it has been shown 
that AVF is associated with a lower mortality rate than AVG in the 
first 12 months after creation. However, the incidence of repeat 
AVF/AVG creation and CVC placement is substantially higher in the 
first 12 moths after AVF creation compared with AVG (32). Although 
grafts require more procedures to maintain patency, fistulas require 
more procedures to establish patency, with the result that overall pa-
tency may not differ substantially between the two forms of perma-
nent access (33). Due to the high primary failure rate and need for 
multiple procedures to maintain patency with a poor patient quality of 
life, the eligibility in elderly patients should be carefully determined 
(34,35). However, in skill hands the endovascular treatment of AVF 
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complications appears to be a valuable approach even in nonage-
narian in view of low invasiveness, low complication rate, and rela-
tively good long-term patency rate (36). Furthermore, a recent analy-
sis from USRDS data between 2005-2007 on the apparent survival 
advantage of AVFs, after adjustment for health status, suggests that 
AVF should still be the VA of choice for elderly individuals beginning 
HD, until more definitive findings eliminating selection bias become 
available (37). The benefits of an AVF over an AVG only become ev-
ident when the use or expected use of the AVF is >18 months, sug-
gesting that patients with a life expectancy of less than 18 months do 
not experience the benefit of the longer patency expected from AVF 
placement (38). A recent decision analysis on the VA choice in inci-
dent HD patients provided evidence that the AVF attempt strategy is 
superior to AVG and CVC with regard to mortality and cost for the 
majority of patient characteristic combinations; on the contrary, in 
women with diabetes and elderly men with diabetes has similar out-
comes, regardless of access type. The advantages of an AVF at-
tempt strategy significantly diminish among older patients, in particu-
lar in women with diabetes (39). In fact, in a survey of European ex-
perts exploring barriers to the fistula-first concept, less than a third of 
the respondents believed that the majority of nephrologists in their 
country would consider AVF creation in a 75-year-old woman with 
comorbidities (40). The VA-related outcomes may be optimized by 
considering individual patient characteristics and a patient based ap-
proach is recommended (41). 
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Surgical strategy in elderly patients 
Several authors have highlighted the problem of early failure, which 
may span from 20 to 60% (42). A scoring system has been derived 
with the ability to predict the likelihood of failure to mature dependent 
on the patient clinical profile including factors such as age (> 65 
years), coronary artery disease, peripheral vascular disease and 
race (10); however, the elderly patients have a higher fistula failure 
rate (43), and the combination of age and diabetes impairs fistula 
outcome with significantly higher failure rates, up to 42% (44). A re-
cent cohort study on the factors predicting failure of AV   
policy in elderly, demonstrates that there is an association of the 
older age, female gender, black race, diabetes, cardiac failure, 
shorter pre-ESRD nephrology care and predialysis AVF failure (45). 
The aging incident ESRD population might require different strate-
gies in order to minimize risk of failure and number of surgical pro-
cedures. A recent meta-analysis showed a significant higher rate of 
radial-cephalic AVF  failure in the elderly compared with the younger, 
with a pooled effect in favor of the elbow fistula (43). The elbow fistu-
la created at the origin of the radial artery is an efficient primary 
choice in elderly patients, and has a higher survival compared to 
wrist and snuff-box AVFs (28,46). In this regard, the bend of the el-
bow area is of great strategic interest for VA surgery. Arteries of ad-
equate size and less affected by atherosclerotic processes, the ve-
nous network connecting the forearm and the arm and presence of a 
patent perforating vein of the elbow allow the surgeon great flexibility 
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in the type of AVF to construct. The perforating vein fistula may be 
preferred in elderly patients with diabetes and hypertension (47). 
Thus, in elderly patients conservation of proximal access sites might 
be of minimal importance due to their limited life expectancy, and a 
more liberal use of proximal access types may be justified (43). 
However, especially in the elderly, a VA conundrum does exist, as 
the distal VA more likely results in lower access blood flow and high 
incidence of early failure, although it has been demonstrated that the 
use of microsurgery enabled the creation of distal AVFs in elderlies > 
70 years with acceptable risk of failure (48); by contrast, the proximal 
VA more likely results in very high access blood flow, increasing the 
risk of steal syndrome and congestive heart failure.  
Conclusions 
It is well known that observational studies that established the supe-
riority of fistulas have important limitations and a randomized study 
comparing mortality with different access strategies is very difficult to 
plan. The risk of biases in studies comparing clinical outcomes by 
HD access type is substantial (49), especially when elderly peoples 
are included. To provide a best VA option in elderly people a seman-
tic paradigm shift has been recently suggested: it should address 
comorbidity as the main subject line, and then age becomes one of 
the many covariants, instead of an independent risk factor for mortal-
ity (50). Age should not be a limiting factor when determining candi-
dacy for AVF creation (51). 
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In conclusion, because of heterogeneity in life expectancy, health 
status, health priorities, and illness experiences, no approach to VA 
can be expected to meet the needs of all older adults with advanced 
kidney disease. In this context, our opinion is that a multidisciplinary 
team should review elderly patients starting on dialysis, aiming to 
identify the most appropriate VA. In these circumstances, we believe 
that dialysis VA selection in the elderly should be guided by  
preference and surgeon experience, based on comprehensive, bal-
anced and unbiased informations, including their relative advantages 
and disadvantages (Table 2), adopting an individualized approach 
that tries to achieve the best outcomes  regardless of age. 
 Key messages  
1) Renal replacement therapy in the elderly raises several issues. 
2) The VA planning in the elderly is different from that in younger 
patients: elderlies could be referred later to reduce the risk of 
creating an AVF that is never used. 
3) The elderly with limited life expectancy may be less likely to 
benefit from an AVF first approach. 
4) The patient  preference for the type of VA should be taken into 
account. 
5) We advice to adopt an individualized approach, regardless of 
age. 
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Final suggestions 
- The Working Group acknowledges that randomized clinical trials, 
eliminating selection biases, are needed for more definitive find-
ings. Current evidence suggests that AVF should still be the VA 
of choice for elderly individuals beginning HD. 
- No specific recommendations targeted for the elderly are provid-
ed in the recent published guidelines. 
- The Working Group believes that in order to achieve good clinical 
practice the nephrologist should strive to get the best VA for each 
patient based on the  knowledge and skill set, comorbidi-
ties, physical examination, ultrasound mapping and surgical 
anatomy, regardless of age. 
- The Working Group suggests that surgical strategies aiming to 
minimize the VA complications, such as the high fistula failure 
rate, steal syndrome and cardiac failure, are necessary in the el-
derly patients. 
- The Working Group suggests that in elderly comorbid patients 
with no useable veins, the AVG placement might be the best op-
tion in order to avoid the CVCs with their inherent high infection 
risk. 
- The Working Group believes that a catheter may be the best VA 
and a better option in end-of-life situations regardless of age. 
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Table 1. Summary of the recommendations and suggestions from 
studies on vascular access in the elderly 
Autho
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Results Notes 
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tive 
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lected 
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Nonage-
narian = 
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age 93.9 
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Only 
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(=30) 
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and 
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ment of 
upper 
limb 
AVF 
(steno-
sis or 
throm-
PPR 
=60% and 
43% 
at 1 and 2 
years 
SPR = 
95% and 
92% at 1 
and 2 
years 
Endo-
vascular 
treatment 
is a valu-
able 
approach 
in nona-
genarian 
patients  
26 
bosis) 
Bon-
forte 
JVA 
2000 
Italy 
Retro-
spec-
tive 
198 pa-
tients > 
65 years 
Tole-
do-
Perei-
ra, 
snuff-
box, 
wrist 
AVF 
Primary 
survival 
Best out-
come 
from prox-
imal radial 
AVF (To-
ledo-
Pereira) 
in spite of 
comorbid-
ities 
Toledo-
Pereira 
AVF 
suggest-
ed as 
first ac-
cess op-
tion in el-
derly 
Bor-
zumati 
JVA 
2013 
Italy 
Retro-
spec-
tive 
78 pts 
Mean 
age 82,5 
years 
 Survival 
and 
compli-
cation 
rate for 
distal, 
mid 
arm, 
proximal 
AVF 
Overall 
survival 
76% and 
71% at 12 
and 24 
months 
for AVF 
Choose 
as distal 
AVF as 
possible 
in elderly. 
AVF is 
gold 
standard 
in elderly 
as 
younger 
27 
pts 
Chang  
Sem 
Dial 
2011  
USA 
Re-
stro-
spec-
tive 
USRD
S 
Wave 
II 
764pts  > 
65 years 
AVF 
vs 
AVG.  
Dia-
betics 
vs non 
diabet-
ics 
Mortality 
and in-
terven-
tion re-
ferral 
No mor-
tality dif-
ferences 
AVF vs 
AVG, for 
interven-
tion refer-
ral for di-
abetics 
and non 
diabetics 
Potential 
benefits 
derived 
from AVF 
com-
pared 
with AVG 
and CVC 
may not 
apply 
univer-
sally. 
 
Cloude
anos 
Ann 
Vasc 
Surg 
2015 
USA 
 
Retro-
spec-
tive 
 
31 pts, 
mean 
age 82 y 
 
32 
AVF 
 
PPR, 
SPR at 
1 and 2 
years 
 
PPR= 
51% and 
38% at 1 
and 2 
years 
SPR = 
75% at 1 
and 2 
 
Doubts 
on ad-
vantages 
of AVF in 
elderly 
28 
years 
 
High level 
of reinter-
vention to 
mantain 
patency, 
high use 
of CVC. 
Poor 
survival 
De 
Leur 
Vasc 
Endov
sc 
Surg 
2013 
Neth-
er-
lands 
Retro-
spec-
tive 
107 AVF 
in 90 pts, 
aged 
75years 
or older 
65 
RCF 
vs 42 
BCF 
PPR 
and 
SPR,  
QOL 
PPR for 
RCF at 1 
and 2 
years = 
31%, 22% 
SPR for 
RCF 1 
and 2 
years 
58%, 50% 
PPR for 
BCF at 1 
and 2 
years = 
Signifi-
cant 
benefit in 
creating 
proximal 
access 
QOL high 
despite a 
high mor-
tality rate 
29 
52%  and 
41% 
SPR for 
BCF at 1 
and 2 
years = 
70% and 
57% 
DeSilv
a 
JASN 
2013 
USA 
Prospe
ctive 
Cohort 
study 
115,425 
Incident 
HD pa-
tients 
Age: 
76.9±6.4
yrs 
Gen-
der:52.9
% male 
Fistula 
Graft 
Cathet
er 
Mortality HR:1.77 
CVC vs 
AVF 
(p<0.001) 
HR:1.05 
Graft vs 
Fistula  
(p=0.06) 
Fistula 
was not 
superior 
to graft 
Hicks 
J Vasc 
Surg 
2015  
USA 
Retro-
spec-
tive 
507791 
pts on 
USRDS 
2006-
2010 
Age 
group 
Mortality AVF is 
superior 
to AVG 
and CVC 
regard-
less of the 
Mortality 
benefit of 
AVG 
over 
CVC may 
not apply 
30 
 
age, in-
cluding in 
octoge-
narians. 
groups 
in older 
(>89 
years) 
age 
groups 
Hod 
JASN 
2014  
USA 
Retro-
spec-
tive 
17511 
pts 
Mean 
Age 76.1 
years at 
the initia-
tion HD 
AVF 
suc-
cess 
group 
(suc-
cess) 
vs 
AVG+
CVC 
group 
(fail-
ure) 
AVF 
success 
initiation 
of HD 
using 
theAVF 
initially 
placed, 
regard-
less of 
the 
func-
tionality 
and du-
rability  
Placing 
an 
AVF.6 9 
months 
predialy-
sis in the 
elderly 
may not 
associate 
with a 
better 
AVF suc-
cess rate 
Succes 
rate AVF 
use in-
crease 
as time 
between 
creation 
and HD 
initiation 
in-
creased( 
but not > 
9 
months) 
31 
Laz-
arides 
J Vasc 
Surg 
2007 
Greec
e 
Meta 
analy-
sis 
Ten 
studies: 
1171 
non el-
derly and 
670 el-
derly  
Only 5 
studies 
with PPR 
and SPR 
Elderly > 
65 y 
Paten-
cy rate 
distal 
vs 
proxi-
mal 
AVF or 
graft 
Distal 
AV: el-
derly vs 
non el-
derly 
Distal 
access 
in elder-
ly vs 
proximal 
or graft 
More risk 
of failure 
in distal 
access in 
elderly 
Signifi-
cant ben-
efit n cre-
ating 
proximal 
access 
A more 
liberal 
use of 
proximal 
access 
types 
may be 
justified 
Murea 
CJAS
N 
2014 
USA 
Retro-
spec-
tive 
2005-
2007 
464 pts 
with 
tCVC 
374 non 
elderly 
(18 74 
years) 
and 90 
elderly 
 
Risk of 
CVC 
infec-
tion in 
age 
group 
Rate of 
cathe-
ter-
related 
blood-
stream 
infection 
(tCVC)  
Hazard 
ratio = 
0.33 for 
catheter-
related 
blood-
stream 
infection 
in the 
elderly   
Lower 
risk of 
catheter-
related 
blood-
stream 
infection 
in elderly 
than 
younger 
pts 
32 
years) 
patients 
Nadea
u-
Fre-
dette 
He-
modial 
Int 
2013 
Cana-
dian 
Retro-
spec-
tive 
2005-
2008 
55 pts > 
80 years  
vs 57 pts 
50-60  
AVF 
and 
AVG 
Primary 
Failure 
Primary 
and 
second-
ary pa-
tency 
PF older 
40% vs 
17% 
younger 
PPR simi-
lar 
Second-
ary pa-
tency 
shorter in 
elderly 
(p=0.005) 
Need of 
a careful 
selection 
and 
evalua-
tion in el-
derly pri-
or to re-
ferral. 
Patient 
based 
approach 
reccmme
nded 
Olsha 
 
J. 
Vasc 
Surg 
2015 
 
Retro-
spec-
tive 
study 
2005-
2009 
146 ac-
cess 
in134 in-
cident  
and 
prevalent 
HD pa-
128 
AVF 
18  
AVG  
Forear
m, 
upper 
Patency 
rate 
non-
matura-
tion rate 
PPR 
39%, 
33%, and 
23% 
 at 12, 24, 
and 36 
mo.  
Age 
alone 
should 
not dis-
qualify 
patients 
older 
33 
Israel tients 
Age: 
85±2.9 
years 
Gender: 
66% 
male 
arm 
AVF, 
AVG 
 
SPR  
92%, 
83%, and 
77%  
at 12, 24, 
and 36 
mo 
 
No differ-
ence be-
tween the 
different 
types of 
accesses 
than 80 
years 
from ac-
cess sur-
gery 
Swin-
dlehur
st 
J. 
Vasc 
Surg 
2011 
UK 
Retro-
spec-
tively 
on 
pro-
spec-
tively 
col-
lected 
data (6 
246 pts  
> 65 
years 
(Group 
A) 
89 pts  < 
65 years 
(Group 
B) 
AVF 
and 
AVG 
PP, 
APP, 
SP, 
ACPR, 
death 
with 
function-
ing con-
duit, 
mean 
Patency 
rates for 
different 
types of 
conduits 
were simi-
lar be-
tween the 
two group 
Failure to 
AVF in 
elderly 
possible 
with high 
patency 
rate, 
short 
hospital 
stay and 
low revi-
34 
years) 
First 
AV at-
tempt 
conduit 
survival, 
failure to 
mature 
mature > 
elderly 
AVG 
higher 
cumula-
tive pa-
tency in 
group A 
sion rate 
Vachh
arajani 
 
CJAS
N 
2011 
 
USA 
Retros
pective 
37 Inci-
dent HD 
patients 
Age:83.4
±3.4yrs 
Gender: 
64% 
male 
Facility 
HD  
Home 
HD 
Day HD 
before 
death 
Facility 
vs home 
52±14 vs 
386±90 
days 
(p<0.05) 
Func-
tional 
status 
and life 
expec-
tancy 
should 
be as-
sessed  
Weale 
J. 
Vasc 
Surg 
2008  
UK 
Retro-
spec-
tive 
658 pts 
Median 
age 68.5 
y 
RCAV
F 
BCAV
F in 
age 
group 
(< 65, 
Usabil-
ity, pri-
mary, 
second-
ary pa-
tency 
Age did 
no affect 
usability, 
primary or 
second-
ary pa-
tency of 
High fail-
ure rate  
Disa-
greement 
with Laz-
arides 
35 
66-79, 
>80 y) 
either 
RCAVFs 
or 
BCAVFs 
study 
Weyde 
 
Blood 
Purif 
2006  
 
Poland 
Retros
pective  
1998-
2004 
131 con-
secutive 
HD pa-
tients. 
Age 79.1 
± 3.6 yrs 
Gender: 
50% 
male 
Only 
AVF 
con-
sidere
d (92% 
fore-
arm) 
Suc-
cessful 
surgery 
Primary 
and 
second-
ary AVF 
patency. 
Patient 
survival 
Success-
ful AVF: 
107/131 
patients 
(82%) 
PPR: 
70% at 6 
mo, 59% 
at 12 mo 
SPR: 
92% at 6 
mo, 84% 
at 12 mo 
Patients 
survival : 
94% at 6 
mo, 88% 
at 12 mo, 
66% at 3 
Possible 
selection 
bias. 
Good pa-
tients 
and AVF 
survival. 
36 
yrs, 45% 
at 5 yrs 
Zhang 
He-
modial 
Int 
2014  
Cana-
da 
Retro-
spec-
tive  
Regis-
try 
39.721pt
s inci-
dents 
27% 65-
74 y 
26% 75-
85 y 
5% >85 
y 
AV ac-
cess 
(AVF 
and 
graft) 
Cathe-
ters 
Mortality 
by vas-
cular 
access 
and age 
category 
Lower ad-
justed 
mortality 
compared 
with cath-
eter use 
in each 
age cate-
gory 
Under-
stand pa-
tient 
prefer-
ence, 
complica-
tions, 
and 
resurce 
use 
AVF= arteriovenous fistula; AVG=arteriovenous graft; 
CVC=central venous catheter; PPR=primary patency rate; 
SPR=secondary patency rate; RCF=radiocephalic fistula; 
BCF=brachiocephalic fistula; QOL=quality of life; PP=primary pa-
tency; APP=assisted primary patency; SP=secondary patency; 
ACPR=assisted cumulative patency rate; PF=primary failure 
 
37 
Table 2. VA advantages and disadvantages in the elderly 
 
 Advantages Disadvantages 
Pre-
emptiv
e AVF 
 No age limit for this 
procedure with ad-
equate vessels 
 Lower infection 
rates compared to 
CVC and AVG 
 Better survival (?) 
 Patients can 
shower 
 Competing risk of death 
before HD start 
 Higher rates of failure to 
mature compared to AVG 
 More AVFs created than 
used (increased morbidity 
and costs) 
AVF 
after 
dialysi
s start 
 Surgery as needed 
 Most functioning 
AVF will be used 
 Advantages of pre-
emptive AVF are 
maintained, but 
CVC is needed 
 Start of dialysis with a 
CVC 
 Higher AVF dysfunction 
and infection rates com-
pared to pre-emptive AVF 
 Higher rates of failure to 
mature compared to AVG 
 With low mean survival, 
actual AVF utilization may 
38 
be short 
AVG  Short timing from 
procedure to use 
(days to weeks) 
 Lower infection 
rates compared to 
CVC 
 Higher cost 
 Needs accurate mainte-
nance with interventional 
procedures 
CVC  Quick and easy 
procedure 
 No needle 
punctures 
 Higher patient 
preference 
 Increased infection rates, 
carrying higher morbidity 
and mortality 
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